↓ Skip to main content

PLOS

A Randomized, Placebo-Controlled Trial of the Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults and Children in a Cholera Endemic Area in Kolkata, India

Overview of attention for article published in PLOS ONE, June 2008
Altmetric Badge

Mentioned by

policy
1 policy source
wikipedia
1 Wikipedia page

Readers on

mendeley
89 Mendeley
Title
A Randomized, Placebo-Controlled Trial of the Bivalent Killed, Whole-Cell, Oral Cholera Vaccine in Adults and Children in a Cholera Endemic Area in Kolkata, India
Published in
PLOS ONE, June 2008
DOI 10.1371/journal.pone.0002323
Pubmed ID
Authors

Dilip Mahalanabis, Anna Lena Lopez, Dipika Sur, Jacqueline Deen, Byomkesh Manna, Suman Kanungo, Lorenz von Seidlein, Rodney Carbis, Seung Hyun Han, Seong Hye Shin, Stephen Attridge, Raman Rao, Jan Holmgren, John Clemens, Sujit K. Bhattacharya

Abstract

An effective vaccine against cholera has been used for public health purposes in Vietnam since the 1990s. This vaccine was reformulated to meet WHO requirements. We assessed the safety and immunogenicity of the reformulated bivalent (Vibrio cholerae 01 and 0139) killed whole cell oral vaccine in a cholera endemic area in Kolkata, India.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Bangladesh 1 1%
Tanzania, United Republic of 1 1%
Ireland 1 1%
India 1 1%
United Kingdom 1 1%
Japan 1 1%
United States 1 1%
Unknown 82 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 19 21%
Student > Master 14 16%
Student > Ph. D. Student 9 10%
Student > Doctoral Student 7 8%
Student > Bachelor 7 8%
Other 20 22%
Unknown 13 15%
Readers by discipline Count As %
Medicine and Dentistry 30 34%
Immunology and Microbiology 8 9%
Agricultural and Biological Sciences 8 9%
Biochemistry, Genetics and Molecular Biology 5 6%
Nursing and Health Professions 5 6%
Other 16 18%
Unknown 17 19%